Results 81 to 90 of about 15,148 (196)

Phase coupling between eye and brain pulsations is bidirectional and modulated by the parasympathetic system – An fMREye study

Acta Ophthalmologica, EarlyView.
Abstract Purpose Physiological pulsations driven by cardiac, respiratory, and vasomotor activity are essential for solute transport within perivascular and perineural cerebrospinal fluid (CSF) pathways that support brain and eye clearance systems. Previous studies have shown that parasympathetic blockade significantly reduces ocular pulsation power and
Ebrahimi Seyed‐Mohsen, Väyrynen Tommi, Huotari Niko, Saarela Ville, Honkamo Marja, Helakari Heta, Järvelä Matti, Korhonen Vesa, Raitamaa Lauri, Kiviniemi Vesa   +9 more
wiley   +1 more source

Identifying regulatory muscle processes in infantile and adult Pompe patients using a multi‐omic and morphological approach

Brain Pathology, EarlyView.
The study highlights differences in the regulatory processes of skeletal muscle, such as sarcomeric contractility, lysosomal and autophagic function, metabolic activity and immune regulation, at transcriptomic and proteomic levels in infantile and adult Pompe disease.
Alexander Schaiter, Keerthika Lohanadan, Alexander Mensch, Andreas Hentschel, Angela Rosenbohm, Cornelia Kornblum, Angela Roth, Tara Procida‐Kowalski, Heidrun H. Krämer, Andreas Hahn, Jörg Höhfeld, Dieter O. Fürst, Werner Stenzel, Peter F. M. van der Ven, Andreas Roos, Marek Bartkuhn, Anne Schänzer   +16 more
wiley   +1 more source

The nitty‐gritty of vascular permeability in cancer: targeting blood endothelium to control metastases

British Journal of Pharmacology, EarlyView.
Blood vascular permeability is a hallmark of cancer and acts as an active driver of metastatic dissemination. Metastasis accounts for the vast majority of cancer deaths, yet most work has focussed on tumour‐intrinsic traits and angiogenesis, while the specific contribution of endothelial barrier regulation to intravasation and extravasation remains ...
Pierre Boucher, Mérone Da Costa Oliveira, Adrien Levesque, Alexandre Rutault, Patrick Savoyaud, Nicolas Bréchot, Stéphane Germain   +6 more
wiley   +1 more source

First Report of RET Fusion‐Positive Lung Adenocarcinoma With Miliary Intrapulmonary Metastases Responsive to Selpercatinib: A Case Report

Clinical Case Reports
Lung cancer presenting with miliary lung metastases on chest computed tomography is associated with poor prognosis. Recent studies indicate that non‐small cell lung cancer harboring driver gene mutations, including rearranged during transfection (RET ...
Soichi Iwanaka, Tadashi Nishimura, Hajime Fujimoto, Daichi Morita, Hitoshi Kuru, Yasumasa Sakakura, Corina N. D'Alessandro‐Gabazza, Taro Yasuma, Esteban C. Gabazza, Masahiro Naito, Hidenori Ibata, Tetsu Kobayashi   +11 more
doaj   +1 more source

Clinicogenomic and treatment outcomes in RET fusion-positive NSCLC: A multicenter study in Latin American Hispanic patients

Cancer Treatment and Research Communications
Background: RET fusions represent a rare but actionable molecular subtype in non-small cell lung cancer (NSCLC), comprising approximately 1 % of cases.
Oscar Arrieta, Andrés F. Cardona, Nicolle Wagner-Gutiérrez, Vladmir Cláudio Cordeiro de Lima, Erick Figueiredo Saldanha, Luis Corrales, Helano Carioca Freitas, Leonardo Gil Santana, Claudio Martín, Diego Enrico, Rodrigo Motta, Jairo Zuluaga, Leonardo Rojas, Alejandro Ruiz-Patiño, Graciela Cruz, Ángel Valencia, Lucia Viola, Sergio Mejía, Stella Martínez, Carlos Carvajal, Natalia Sánchez, Liliana Gutierrez, Briegel de las Salas, Luis Raez, Christian Rolfo   +24 more
doaj   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Molecular Characterisations and the Association with Clinical Factors in RET Fusion-Positive NSCLC: A Retrospective Study of the Single Center Cohort

Cancer Management and Research
Xiang Li,1 Peiyan Zhao,1 Heran Cui,2 Tingting Zhang,3 Wenyu Sun,3 Hui Li1 1Translational Oncology Research Lab, Jilin Provincial Key Laboratory of Molecular Diagnostics for Malignant Tumor, Jilin Cancer Hospital, Changchun, People’s Republic of China ...
Li X, Zhao P, Cui H, Zhang T, Sun W, Li H   +5 more
doaj  

Pralsetinib: A Drug Review

Indian Journal of Medical and Paediatric Oncology
REarranged during Transfection (RET) is a transforming proto-oncogene that codes for the tyrosine kinase receptor. Pralsetinib is an orally bioavailable, selective inhibitor of mutant forms and fusions involving the RET proto-oncogene.
Abha Deshpande, Ryan Varghese, Jainam Karsiya, Praveen Jha, Padmaj Kulkarni   +4 more
doaj   +1 more source

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

Cancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda, Kazuo Hasegawa, Takayuki Takahama, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Masashi Yoshida, Miyuki Sakai, Sachiko Watanabe, Kazuhiko Nakagawa   +9 more
wiley   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source